Effectiveness of canagliflozin with atorvastatin on dexamethasone-induced dyslipidemia and hepatic steatosis in albino rats
Shaaban, A., Ahmed, E., Abdel Latif, A. (2018). Effectiveness of canagliflozin with atorvastatin on dexamethasone-induced dyslipidemia and hepatic steatosis in albino rats. EKB Journal Management System, 14(1), 246-258. doi: 10.21608/blj.2018.47624
Amany M Shaaban; Eman I Ahmed; Abdel Karim M Abdel Latif. "Effectiveness of canagliflozin with atorvastatin on dexamethasone-induced dyslipidemia and hepatic steatosis in albino rats". EKB Journal Management System, 14, 1, 2018, 246-258. doi: 10.21608/blj.2018.47624
Shaaban, A., Ahmed, E., Abdel Latif, A. (2018). 'Effectiveness of canagliflozin with atorvastatin on dexamethasone-induced dyslipidemia and hepatic steatosis in albino rats', EKB Journal Management System, 14(1), pp. 246-258. doi: 10.21608/blj.2018.47624
Shaaban, A., Ahmed, E., Abdel Latif, A. Effectiveness of canagliflozin with atorvastatin on dexamethasone-induced dyslipidemia and hepatic steatosis in albino rats. EKB Journal Management System, 2018; 14(1): 246-258. doi: 10.21608/blj.2018.47624

Effectiveness of canagliflozin with atorvastatin on dexamethasone-induced dyslipidemia and hepatic steatosis in albino rats

Biochemistry Letters
Article 20, Volume 14, Issue 1, 2018, Page 246-258  XML PDF (763.03 K)
Document Type: Original Article
DOI: 10.21608/blj.2018.47624
View on SCiNiTO View on SCiNiTO
Authors
Amany M Shaaban1; Eman I Ahmed2; Abdel Karim M Abdel Latif3
1Chemistry Department, Faculty of Science, El Fayoum University, El- Fayoum, Egypt
2Pharmacology Department, Faculty of medicine, El Fayoum University, El- Fayoum, Egypt
3Zoology Department, Faculty of Science, El Fayoum University, El- Fayoum, Egypt.
Abstract
Background: NAFLD is the most common liver disease all over the world. NASH can develop cirrhosis and hepatocellular carcinoma. Aim: Our research pointed to study the preventive effects of canagliflozin (CANA) or atorvastatin (ATO) on dexamethasone induced dyslipidemia and hepatic steatosis. Subjects and methods: Animals were grouped as control group; DEX group; ATO/DEX treated group; CANA/DEX treated group and ATO+CANA/DEX treated group. Results: Significant elevations in GSH, SOD and CAT activities, while high significant decreases in serum GOT, GPT, ALP, urea, blood glucose, CK-MB, LDH, T.G, T.C, MDA and P.C levels were demonstrated in treated groups as compared to DEX group in the experimental periods. Also, significant reductions in SGPT, SGPT, ALP, CK-MB, LDH, T.C and T.G levels were detected in CANA/DEX group as compared to ATO/DEX group. All these results were confirmed with histopathological findings where the severe damages and fatty degeneration in both kidney and liver tissues developed by dexamethasone administration resolved by administration of atorvastatin alone or better with Canagliflozin. Conclusion: These results indicate that antioxidant and hypolipidemic effects of canagliflozin may be responsible for the beneficial effects. Also, Canagliflozin was as effective as atorvastatin or combination of both in reducing dyslipidemia and hepatic steatosis. 
Keywords
Canagliflozin; Atorvastatin; Oxidative Stress; dexamethasone; steatosis and dyslipidemia
Statistics
Article View: 207
PDF Download: 281